The Effects of Intravitreal Ophthalmic Medications on Intraocular Pressure

REFERENCES

• Von Sallmann L, Meyer K, Di Grandi J. Experimental study of penilillin treatment of ectogenous infection of vitreous. Arch Ophthalmol 1944; 32: 179
   Google Scholar
• Duguid J P, Ginsberg M, Fraser I C, et al. Experimental observations on the intraviteous use of penicillin and other drugs. Br J Ophthalmol Apr, 1947; 31(4)193–211
   Google Scholar
• Daily M J, Peyman G A, Fishman G. Intravitreal injection of methicillin for treatment of endophthalmitis. Am J Ophthalmol Sep, 1973; 76(3)343–350
   PubMed Web of Science ®Google Scholar
• Peyman G A, Vastine D W, Meisels H I. The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis. Doc Ophthalmol Nov 21, 1975; 39(1)183–201
   PubMed Web of Science ®Google Scholar
• Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol Jan 15, 1987; 103(1)17–23
   Google Scholar
• Luu K K, Scott I U, Chaudhry N A, et al. Intravitreal antiviral injections as adjunctive therapy in the management of immunocompetent patients with necrotizing herpetic retinopathy. Am J Ophthalmol Jun, 2000; 129(6)811–813
   Google Scholar
• Blankenship G W. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefes Arch Clin Exp Ophthalmol 1991; 229(1)62–65
   Google Scholar
• Penfold P L, Gyory J F, Hunyor A B, Billson F A. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol Nov, 1995; 23(4)293–298
   Google Scholar
• Gillies M C, Simpson J M, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol May, 2003; 121(5)667–673
   Google Scholar
• Jonas J B, Kreissig I, Degenring R F. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol Aug, 2003; 136(2)384–386
   PubMed Web of Science ®Google Scholar
• Gómez-Ulla F, Marticorena J, Alfaro D V, 3rd, et al. Intravitreal triamcinolone for the treatment of diabetic macular edema. Curr Diabetes Rev Feb, 2006; 2(1)99–112
   Google Scholar
• Alldredge C D, Garretson B R. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003; 23: 113–6
   PubMed Web of Science ®Google Scholar
• Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology Nov, 2005; 112(11)e1–e7, 1916
   Google Scholar
• Jonas J B, Hayler J K, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468–471
   PubMed Web of Science ®Google Scholar
• Gragoudas E S, Adamis A P, Cunningham E T, Jr, , VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med Dec 30, 2004; 351(27)2805–2816
   PubMed Web of Science ®Google Scholar
• Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol Aug, 2008; 92(8)1035–1039
   Google Scholar
• Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina Nov-Dec, 2006; 26(9)999–1005
   PubMed Web of Science ®Google Scholar
• Costa R A, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina Feb, 2007; 27(2)141–149
   Google Scholar
• Han D P. Endophthalmitis. Ophthalmic Surgery: Principles and Techniques, D M Alber. Blackwell Science, Malden 1999; 650–662
   Google Scholar
• De Clercq E. Antiviral drugs in current clinical use. J Clin Virol Jun, 2004; 30(2)115–133
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2004; 26: 859–870
   Google Scholar
• Tsamparlakis J C. Effects of transient induced elevation of the intraocular pressure on the visual field. Br J Ophthalmol May, 1964; 48: 237–249
   Google Scholar
• Scott A B, Morris A. Visual field changes produced by artificially elevated intraocular pressure. Am J Ophthalmol Feb, 1967; 63(2)308–312
   Google Scholar
• Moster M R, Moster M L. Wipe-out: A complication of glaucoma surgery or just a blast from the past?. Am J Ophthalmol Oct, 2005; 140(4)705–706
   Google Scholar
• Lanzl I M, Moster M R, Hodges D D. Intraoperative prediction of intraocular pressure for the first postoperative day following glaucoma filtration surgery. Ophthalmic Surg Lasers Sep, 1997; 28(9)780–782
   Google Scholar
• Moster M R, et al. Invest Ophthalmol Vis Sci 1987; 28(suppl)273
   Google Scholar
• Falkenstein I A, Cheng L, Freeman W R. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007; 27: 1044–1047
   PubMed Web of Science ®Google Scholar
• Kim J E, Mantravadi A V, Hur E Y, Covert D J. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol Dec, 2008; 146(6)930–934
   Google Scholar
• Hariprasad S M, Shah G K, Blinder K J. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 2006; 141: 200–201
   PubMedGoogle Scholar
• Lee E W, Hariprasad S M, Mieler W F, et al. Short-term intraocular pressure trends after intravitreal triamcinolone injection. Am J Ophthalmol 2007; 143: 365–367
   Google Scholar
• Benz M S, Albini T A, Holz E R, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006; 113: 1174–1178
   PubMedGoogle Scholar
• Bakri S J, Pulido J S, McCannel C A, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye, In press
   Google Scholar
• Mojica G, Hariprasad S M, Jager R D, Mieler W F. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol Apr, 2008; 92(4)584
   Google Scholar
• Morlet N, Young S H. Prevention of intraocular pressure rise following intravitreal injection. Br J Ophthalmol Sep, 1993; 77(9)572–573
   Google Scholar
• Hollands H, Wong J, Bruemn R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807–811
   PubMed Web of Science ®Google Scholar
• Frenkel R E, Mani L, Toler A R, Frenkel M P. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol Jun, 2007; 143(6)1034–1035
   Google Scholar
• Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: Clinical results and biomechanical model. Acta Ophthalmol Scand Nov, 2007; 85(7)777–781
   Google Scholar
• Pallikaris I G, Kymionis G D, Ginis H S, et al. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci Feb, 2005; 46(2)409–414
   PubMed Web of Science ®Google Scholar
• Jonas J B, Kreissig I, Degenring R F. Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol Feb, 2004; 242(2)184–185
   Google Scholar
• Lau L I, Chen K C, Lee F L, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol Oct, 2008; 146(4)573–578
   Google Scholar
• Im L, Allingham R R, Singh I, et al. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. J Glaucoma Mar, 2008; 17(2)128–132
   Google Scholar
• Inatani M, Iwao K, Kawaji T, et al. Intraocular pressure elevation after injection of triamcinolone acetonide: A multicenter retrospective case-control study. Am J Ophthalmol Apr, 2008; 145(4)676–681
   Google Scholar
• Rhee D J, Peck R E, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol Aug, 2006; 90(8)999–1003
   PubMed Web of Science ®Google Scholar
• Jonas J B, Degenring R F, Kreissig I, Akkoyun I, Kamppeter B A. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593–598
   PubMed Web of Science ®Google Scholar
• Jonas J B, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol Jan, 2003; 87(1)24–27
   PubMed Web of Science ®Google Scholar
• Jonas J B, Degenring R, Kreissig I, et al. Safety of intravitreal high-dose reinjections of treiamcinoloneacetonide. Am J Ophthalmol Dec, 2004; 138(6)1054–1055
   Google Scholar
• Smithen L M, Ober M D, Maranan L, Spaide R F. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol Nov, 2004; 138(5)740–743
   PubMed Web of Science ®Google Scholar
• Gillies M C, Simpson J M, Billson F A, et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004; 122(3)336–340
   PubMedGoogle Scholar
• Park H Y, Yi K, Kim H K. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol Jun, 2005; 19(2)122–127
   Google Scholar
• Vasconcelos-Santos D V, Nehemy P G, Schachat A P, Nehemy M B. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: Incidence and risk factors. Retina 2008; 28: 573–580
   PubMed Web of Science ®Google Scholar
• Shields M B. Steroid-induced glaucoma. Textbook of Glaucoma, 3rd edition, M B Shields. Williams & Wilkins, Baltimore 1992; 374–380
   Google Scholar
• Kubota T, Okabe H, Hisatomi T, et al. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006; 15(2)117–119
   Google Scholar
• Shinzato M, Yamashiro Y, Miyara N, et al. Proteomic analysis of the trabecular meshwork of rats in a steroid-induced ocular hypertension model: Downregulation of type I collagen C-propeptides. Ophthalmic Res 2007; 39(6)330–337
   Google Scholar
• Rozsa F W, Reed D M, Scott K M, et al. Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis 2006; 12: 125–141
   PubMed Web of Science ®Google Scholar
• Bill A. The drainage of aqueous humor. Invest Ophthal 1975; 14: 1
   PubMedGoogle Scholar
• Singh I P, Ahmad S I, Yeh D, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol Aug, 2004; 138(2)286–287
   Google Scholar
• Brown D M, Kaiser P K, Michels M, , ANCHOR Study Group, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med Oct 5, 2006; 355(14)1432–1444
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Brown D M, Heier J S, , MARINA Study Group, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med Oct 5, 2006; 355(14)1419–1431
   PubMed Web of Science ®Google Scholar
• Wu L, Martínez-Castellanos M A, Quiroz-Mercado H, , for the Pan American Collaborative Retina Group (PACORES), et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol Jan, 2008; 246(1)81–87
   PubMed Web of Science ®Google Scholar
• Bakri S J, McCannel C A, Edwards A O, Moshfeghi D M. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol Jul, 2008; 246(7)955–958, In press
   PubMed Web of Science ®Google Scholar
• Jalil A, Fenerty C, Charles S. Intravitreale bevacizumab (Avastin) causing acute glaucoma: An unreported complication. Eye Dec, 2007; 21(12)1541, In press
   PubMed Web of Science ®Google Scholar
• Kahook M Y, Kimura A E, Wong L J, et al. Sustained elevation in intraocular pressure associated with intravitreal Bevacizumab injections. Ophthalmic Surg Lasers Imaging, In press
   Google Scholar
• Krohne T U, Eter N, Holz F G, Meyer C H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol Oct, 2008; 146(4)508–512, In press
   PubMed Web of Science ®Google Scholar
• Rich R M, Rosenfeld P J, Puliafito C A, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495–511
   PubMed Web of Science ®Google Scholar
• Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7(4)335–345, In press
   PubMedGoogle Scholar
• Mordenti J, Cuthbertson R A, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol Sep-Oct, 1999; 27(5)536–544
   PubMed Web of Science ®Google Scholar
• Banker A S, Arevalo J F, Munguia D, et al. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol Aug, 1997; 124(2)168–180
   PubMed Web of Science ®Google Scholar
• Taskintuna I, Banker A S, Rao N A, et al. An animal model for cidofovir (HPMPC) toxicity: Intraocular pressure and histopathologic effects. Exp Eye Res May, 1997; 64(5)795–806
   PubMed Web of Science ®Google Scholar